Long-Term Vision “Vision 110”

Long-Term vision

Vision 110

FY2023-FY2032

Our vision to become “a company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value new drugs that meet medical needs”. We will strive to achieve this goal.

Long-term vision “Vision 110”

To embody our corporate philosophy—"Kyorin shall fulfill its social mission of contributing to better health by cherishing life"—the Group is advancing its long-term vision, "Vision 110" (FY2023-2032), with a clear focus on our 110th anniversary in 2033.

More detail

Outline of Vision 110 -Stage 2-

As of fiscal 2026, we have launched our new medium-term business plan, "Vision 110 -Stage 2-." We are committed to promoting our five key business strategies to ensure the achievement of our Exit Targets.

More detail

Strategy of Vision 110 -Stage 2-

Under the medium-term business plan "Vision 110 -Stage 2-," we will focus on the following key initiatives: "Expanding our development pipeline through proactive in-licensing investment," "Strengthening our capability to create high-value new drugs that meet medical needs," "Maximizing the uptake of new drugs," "Promoting health-related businesses that create synergies with our innovative drug business," and "Building a sustainable corporate foundation."

More detail

Exit Targets in Vision 110 -Stage 2-

Kyorin Group set exit Targets for improvement corporate value and sustainable growth.

More detail